What is Zevra Therapeutics, Inc.'s net change in cash?

Zevra Therapeutics, Inc. (ZVRA) reported net change in cash of $33.19M in Q1 2026.

How has Zevra Therapeutics, Inc.'s net change in cash changed year-over-year?

Zevra Therapeutics, Inc.'s net change in cash increased by 833.6% year-over-year, from $3.56M to $33.19M.

What is the long-term trend for Zevra Therapeutics, Inc.'s net change in cash?

Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s net change in cash has grown at a -15.2% compound annual growth rate (CAGR), from -$46.88M to $28.62M.

What does net change in cash mean?

Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.

Zevra Therapeutics, Inc. ZVRA Net Change in Cash

Net Change in Cash at other companies

BioMarin PharmaceuticalsBMRN

$1.76B+1,562%

Ultragenyx PharmaceuticalRARE

-$247M-449%

XER

Xeris Biopharma Holdings, Inc.XERS

$708K+105%

Eton Pharmaceuticals, Inc.ETON

-$6.28M-353%

Theravance BiopharmaTBPH

$120.3M+65.2%

Relay Therapeutics, Inc.RLAY

$120.57M+492%

Other financials

Income statement

See full

Revenue$36.2M+77.5%

Gross profit$34.3M+80.1%

Operating income$52.1M+1,073%

Net income$37.9M+1,323%

EPS (diluted)$0.60+1,100%

Balance sheet

See full

Cash & equivalents$95.6M+156%

Total debt$1.1M-98.1%

Total equity$205.8M+402%

Total assets$278.6M+61.3%

Cash flow

See full

Operating cash flow$6.1M+175%

CapEx$35.0K-64.6%

Free cash flow$6.1M+173%

Valuation

See full

Market cap$773.23M+56.4%

Enterprise value$678.78M+30.8%

P/E6.2×—

P/S6.3×-5.9×

Profitability

See full

Gross margin86.1%+7.2pp

Operating margin-103.9%-43.0pp

Net margin101.6%+60.1pp

FCF margin-75%-30.5pp

Returns & leverage

See full

Return on equity100.7%+60.3pp

Debt / equity0×-1.5×

Current ratio4.9×+1.9×

Where this comes from

Reported directly by Zevra Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.

The official record: Zevra Therapeutics, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zevra Therapeutics, Inc.'s net change in cash.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Zevra Therapeutics, Inc.'s net change in cash?: Zevra Therapeutics, Inc. (ZVRA) reported net change in cash of $33.19M in Q1 2026.
How has Zevra Therapeutics, Inc.'s net change in cash changed year-over-year?: Zevra Therapeutics, Inc.'s net change in cash increased by 833.6% year-over-year, from $3.56M to $33.19M.
What is the long-term trend for Zevra Therapeutics, Inc.'s net change in cash?: Over 3 years (2022 to 2025), Zevra Therapeutics, Inc.'s net change in cash has grown at a -15.2% compound annual growth rate (CAGR), from -$46.88M to $28.62M.
What does net change in cash mean?: Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.